Daliresp
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Roflumilast therapy has a limited role in patients with severe COPD, and no role in patients with mild to moderate COPD. It will…
PURPOSE
The pharmacology, pharmacokinetics, efficacy, and safety of roflumilast-the first in a new class of agents for managing…
Objective To identify the structure of the new drug daliresp. Methods The structure of daliresp w as identified by UV,IR,MS,1H…
APIXABAN (ELIQUIS®) FOR ORAL ANTICOAGULATION IN NONVALVULAR ATRIAL FIBRILLATION hronic obstructive pulmonary disease (COPD) is a…
is substantial. Quality of life, morbidity, and mortality are all negatively affected by the disease. In the National Health and…
Roflumilast (Daxas® [EU], Daliresp® [USA]) is the first phosphodiesterase 4 inhibitor approved in Europe to be used in severe…
roflumilast Chronic obstructive pulmonary disease (COPD) is a progressive, irreversible lung disease that is often associated…
New molecular entity: Roflumilast oral treatment was approved by FDA as treatment to reduce risk of COPD exacerbations.